Olanzapine - Revision history

MDElliottMD: parser-claude: Olanzapine MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:12:15Z

parser-claude: Olanzapine MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:12, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Olanzapine		\| generic = Olanzapine
	\| brand = Zyprexa		\| brand = Zyprexa (oral, IM acute), Zyprexa Zydis (ODT), Zyprexa Relprevv (LAI), Lybalvi (with samidorphan)
	\| structure =		\| structure =
	\| classes = ~~Antipsychotic~~, ~~Neuroleptic~~		\| classes = [[:Category:Neuroleptics\|Neuroleptic]], [[:Category:Atypical neuroleptics\|Atypical neuroleptic (second-generation)]], [[:Category:Thienobenzodiazepines\|Thienobenzodiazepine]], [[:Category:Mood stabilizers\|Mood stabilizer]]
	\| ~~mechanism~~ = ~~Multi~~-~~receptor antagonist~~ (D1-4, 5-~~HT2~~, H1, ~~muscarinic~~)		\| uses = <vote slug="schizophrenia-use">Schizophrenia (FDA)</vote>, <vote slug="bipolar-mania-mixed-use">Bipolar I mania and mixed episodes (FDA)</vote>, <vote slug="bipolar-maintenance-use">Bipolar I maintenance (FDA)</vote>, <vote slug="bipolar-depression-combination-use">Bipolar depression (FDA, in combination with fluoxetine as Symbyax)</vote>, <vote slug="acute-agitation-im-use">Acute agitation in schizophrenia or bipolar disorder (FDA, IM)</vote>, <vote slug="treatment-resistant-depression-adjunct-use">Treatment-resistant depression adjunct (off-label)</vote>, <vote slug="anorexia-nervosa-use">Anorexia nervosa (off-label, evidence-supported)</vote>
	\| ~~uses~~ =		\| starting_dose = Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap
	\| ~~starting_dose~~ =		\| preparations = Tablets 2.5, 5, 7.5, 10, 15, 20 mg; ODT (Zydis) 5, 10, 15, 20 mg; acute IM injection 10 mg/vial; Relprevv LAI 210, 300, 405 mg vials
	\| ~~preparations~~ =		\| fda_max = 20 mg/day (oral)
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral, intramuscular (acute and long-acting)
	\| onset =		\| onset = Sedation from first dose; neuroleptic effect emerges over days to weeks
	\| duration =		\| duration = 24 hours (oral); 2-4 weeks (LAI)
	\| halflife =		\| halflife = 21-54 hours<ref name="zyprexa-label">FDA Prescribing Information, Zyprexa (olanzapine), Eli Lilly, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020592s062,021086s041,021253s048lbl.pdf</ref>
	\| bioavailability =		\| bioavailability = ~60% (oral); ~100% (IM)<ref name="zyprexa-label" />
	\| pregnancy =		\| pregnancy = Signal for gestational diabetes and metabolic syndrome with maternal exposure; the metabolic load can be substantial during pregnancy.{{citation needed}}
	\| legal =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly patients with dementia-related psychosis. '''Zyprexa Relprevv LAI''' additionally carries a Boxed Warning for '''post-injection delirium/sedation syndrome''' requiring 3-hour monitored observation after each injection<ref name="zyprexa-label" />
	\| ~~intro~~ =		\| mechanism = <vote slug="olanzapine-mech-claim">Multi-receptor antagonist with broad activity at D1, D2, D3, D4 dopamine receptors (D2/D3 mediating the neuroleptic effect), 5-HT2A and 5-HT2C serotonin receptors (the atypical-neuroleptic feature, reducing extrapyramidal burden), H1 histamine (mediating sedation and weight gain), M1-M5 muscarinic (anticholinergic effects), and α1-adrenergic (orthostatic hypotension) receptors.</vote> The marquee tolerability concern is '''severe metabolic burden''': weight gain often exceeding 10 kg in the first year, insulin resistance, hyperlipidemia, and elevated type 2 diabetes risk, among the worst in the second-generation class. Routine metabolic monitoring (weight, fasting glucose, lipid panel) is standard. The Lybalvi formulation combines olanzapine with samidorphan, an opioid antagonist, to mitigate weight gain<ref name="zyprexa-label" />.
	\| ~~pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	~~\| indications =~~
	~~\| dosing =~~
	\| effects =
	~~\| interactions =~~ <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	\| monitoring =
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	~~[[Category:Second-generation neuroleptics]]~~		== References ==
			<references />

	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
			[[Category:Atypical neuroleptics]]
			[[Category:Thienobenzodiazepines]]
			[[Category:Mood stabilizers]]

MDElliottMD: Category taxonomy (#23): retag to house-compliant neuroleptic categories

2026-05-22T14:41:27Z

Category taxonomy (#23): retag to house-compliant neuroleptic categories

← Older revision		Revision as of 14:41, 22 May 2026
Line 31:		Line 31:
	}}		}}

	[[Category:Second-~~Generation Antipsychotics (SGAs / Atypicals)~~]]		[[Category:Second-generation neuroleptics]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged.

2026-05-19T18:00:17Z

Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 31:		Line 31:
	}}		}}


	~~[[Category:Antipsychotics / Neuroleptics]]~~
	[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]		[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:51Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Antipsychotics / Neuroleptics]]
			[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:03Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:44Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:40Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Olanzapine
+| generic            = Olanzapine
-| brand             = Zyprexa
+| brand              = Zyprexa
-| classes           = Antipsychotic, Neuroleptic
+| structure          =
-| mechanism         = Multi-receptor antagonist (D1-4, 5-HT2, H1, muscarinic)
+| classes            = Antipsychotic, Neuroleptic
 }}
 [[Category:Neuroleptics]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Olanzapine
| brand = Zyprexa
| classes = Antipsychotic, Neuroleptic
| mechanism = Multi-receptor antagonist (D1-4, 5-HT2, H1, muscarinic)
}}
[[Category:Neuroleptics]]